Welcome to our dedicated page for Quantum-Si Incorporated news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si Incorporated stock.
Quantum-Si Incorporated (symbol: QSI) is revolutionizing the field of proteomics with cutting-edge technologies. The company has developed a unique semiconductor chip that enables single-molecule, next-generation protein sequencing and genomics, going beyond traditional DNA sequencing. This innovation is set to digitize proteomic research, significantly advancing drug discovery and diagnostics.
Founded by successful entrepreneurs and fully funded to focus on groundbreaking science, Quantum-Si fosters an environment where highly committed individuals are encouraged to solve tough problems and create impactful technologies. The company is headquartered in Guilford, Connecticut, and continues to attract bright minds dedicated to transforming healthcare.
Quantum-Si's core products include a suite of technologies that leverage their proprietary semiconductor chip for high-precision protein analysis. These products are designed to provide deeper insights into the proteome, which is essential for understanding diseases, developing new therapies, and personalizing medicine.
Recent achievements highlight Quantum-Si's commitment to innovation and excellence. The company has formed strategic partnerships with leading research institutions and pharmaceutical companies to accelerate the adoption of its technologies. Additionally, Quantum-Si continues to invest in research and development to enhance its product offerings and expand its market reach.
Financially, Quantum-Si is backed by substantial funding from its founders, allowing the company to prioritize innovation and market entry without the immediate pressures of profitability. This financial stability ensures that the company can focus on long-term goals and sustainable growth.
For those interested in joining a dynamic and innovative team, Quantum-Si offers a range of career opportunities. Visit their job postings at 4Catalyzer to learn more about current openings.
Empower discovery. Empower health. Empower you.
Quantum-Si (NASDAQ: QSI) has acquired Majelac Technologies LLC, enhancing its semiconductor chip assembly and packaging capabilities. This acquisition aims to secure Quantum-Si's supply chain and support the scaling of its commercialization efforts. CEO John Stark emphasized that in-house chip assembly will expedite operations to meet demand amid global semiconductor supply challenges. The integration of Majelac, known for its quick-turn assembly services, is expected to bolster Quantum-Si's mission to innovate in proteomics research.
Quantum-Si Incorporated (NASDAQ: QSI) announced its participation in the 2021 Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum. CEO John Stark and CFO Claudia Drayton will engage in a virtual fireside chat on Thursday, November 18, 2021, at 2:30 p.m. ET. Interested parties can access a webcast on the Investors section of Quantum-Si's website, with a replay available post-event. Founded in 2013 by Dr. Jonathan Rothberg, Quantum-Si focuses on advancing proteomics through its unique protein sequencing technology powered by a groundbreaking semiconductor chip.
Detect, Inc. announces that its PCR-quality at-home Covid-19 Test has received Emergency Use Authorization from the U.S. FDA. The test provides results in one hour, making it ideal for home, school, and workplace use. With an overall agreement of 97.3%, a sensitivity of 90.9%, and 100% specificity, it is among the most accurate home tests available. Priced under $50, it stands as the lowest-cost molecular test on the market. The test is designed to detect all current variants of concern and is supported by an $8.1 million NIH contract to scale up manufacturing.
Quantum-Si (NASDAQ:QSI) will report its Q3 2021 financial results on November 11, 2021, before market open. CEO John Stark and CFO Claudia Drayton will host a conference call at 8:30 a.m. ET on the same day to discuss the financial results and provide a business update. The call will be accessible via webcast and by phone.
Quantum-Si (NASDAQ: QSI) has expanded its Platinum early access program to ten global sites, including notable academic centers and industry partners. This initiative aims to enhance understanding of the proteome, which currently sees only 2% of its estimated million protein structures analyzed. The program supports the development of multi-omic assays and advanced biomarker characterization, positioning Quantum-Si to address critical biological research needs. CEO John Stark emphasizes the company's momentum in transforming proteomics and advancing drug discovery.
Detect, Inc. has secured an $8.1 million funding award from the National Institutes of Health (NIH) under the RADx initiative to advance its Detect™ Covid-19 Test. This test is currently pending FDA Emergency Use Authorization and promises PCR-quality results at home in approximately one hour. The funding will aid in scaling manufacturing to meet national demand. Designed for schools, businesses, and homes, the Detect Covid-19 Test targets all known Covid-19 variants, including Delta, enhancing accessible testing options in the U.S.
Quantum-Si Incorporated (NASDAQ: QSI) announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27-30, 2021. CEO John Stark and CFO Claudia Drayton will host a virtual fireside chat on September 29 from 1:20 to 1:50 PM EDT. Quantum-Si is focused on advancing proteomics through a novel semiconductor chip enabling next-generation protein sequencing. For more details, visit the Investor Relations section on their website.
Founded in 2013 by Dr. Jonathan Rothberg, Quantum-Si aims to transform drug discovery and diagnostics.
Quantum-Si (Nasdaq: QSI) announced its second-quarter 2021 financial results, highlighting a net loss of $35.7 million, up from a loss of $8.2 million in Q2 2020. Operating expenses surged to $32.2 million, a 292% increase year-over-year. Positive developments included the completion of a business combination with HighCape, adding over $511 million in cash, and the delivery of five early access systems to key thought leaders in the proteomics field. The company plans to build a 25,000 square foot facility in San Diego to enhance R&D and production capabilities.
Quantum-Si announced the rescheduling of its second quarter 2021 financial results conference call to August 16, 2021, post-market close. CEO John Stark and CFO Claudia Drayton will host the call at 4:30 p.m. ET to discuss financial results and a business update. The call will be available via webcast on the Investor Relations website. Quantum-Si, founded in 2013, focuses on semiconductor chip-based proteomics, leveraging technology aimed at advancing drug discovery and diagnostics beyond DNA sequencing.
Quantum-Si Incorporated plans to report its second quarter 2021 financial results on August 12, 2021, prior to market opening. CEO John Stark and CFO Claudia Drayton will hold a conference call at 8:30 a.m. ET on the same day to discuss the results and provide a business update. The call can be accessed via a live webcast on the company's Investor Relations website. Quantum-Si is focused on advancing proteomics through innovative semiconductor technology for protein sequencing.
FAQ
What is the current stock price of Quantum-Si Incorporated (QSI)?
What is the market cap of Quantum-Si Incorporated (QSI)?
What does Quantum-Si Incorporated do?
What is the significance of Quantum-Si's semiconductor chip?
Where is Quantum-Si headquartered?
Who funds Quantum-Si?
What are Quantum-Si's core products?
What recent achievements has Quantum-Si made?
What opportunities are available at Quantum-Si?
How does Quantum-Si contribute to healthcare?
What is the financial condition of Quantum-Si?
How can I stay updated with the latest news about Quantum-Si?
